Markets
Mankind Pharma Reports Strong Performance Across Chronic and Acute Portfolios in FY27
Originally reported by ET Industry as: Mankind Pharma shares key business developments from Q2 & H1 of FY27
26 Oct 2026, 5:48 pm IST · Xecute.finance News Desk
The crisp read
Mankind Pharma released its Q2 and H1 FY27 business updates, highlighting outperformance across therapeutic segments. Cardiac and anti-diabetes portfolios grew by 18.7% and 15.8% respectively, while acute therapies also showed robust expansion. Gastroenterology and nutritional brands grew at multiples of the wider market rate.
Why it matters: Provides healthcare analysts and investors with segment-wise growth metrics for a major Indian pharmaceutical firm.
Deep dive - the full story
Mankind Pharma has shared key business developments covering the second quarter and the first half of fiscal year 2027. The pharmaceutical firm reported outperforming the broader market by 1.1 times across both chronic and acute therapeutic segments. Within chronic care, cardiac and anti-diabetes brands posted notable growth figures of 18.7% and 15.8% respectively.
In acute therapies, the gastroenterology portfolio expanded at 1.3 times the prevailing market rate. Simultaneously, the vitamins, minerals, and nutrients division achieved growth at 1.4 times the market rate, reflecting solid demand across key consumer health categories.
Investors and market analysts should incorporate these therapeutic growth multiples into their evaluation of the company's operational trajectory. Management will likely reference these portfolio drivers in upcoming earnings discussions and strategic briefings.
Source: economictimes.indiatimes.com
This is news/educational content, not investment advice. Xecute.finance is not SEBI-registered. Consult a qualified professional before acting.
Reading the static edition.
The live app adds Ask Xecute, deadline trackers, the daily quiz and one-tap deep dives.
Open this story in the Xecute app →Xecute.finance · India's AI-powered finance daily · Founded & built by Kanishk Singh Sikarwar